Evidence map›Paper›PMID 17703310›Full record

ReviewWorld journal of urology2007

Mass spectrometry based proteomics in urine biomarker discovery.

Dan Theodorescu, Harald Mischak

Abstract readReview
PubMed Publisher
In one paragraph

Review in World journal of urology, 2007. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed.

  1. Review
  2. Review
  3. Review
  4. Review
  5. Review
  6. Review
  7. Review
  8. Prediction of preeclampsia-bench to bedside.Current hypertension reports · 2014
    Review
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Dan TheodorescuDepartment of Molecular Physiology, University of Virginia, Charlottesville, USA.
Harald Mischak

Funding

Regulation and Targeting of CD24 in Bladder CancerR01CA075115 · NCI · UNIVERSITY OF VIRGINIA CHARLOTTESVILLE · PI THEODORESCU, DAN · 2003 to 2024
$7.0M
MECHANISMS OF BLADDER CANCER INVANSIONR29CA075115 · NCI · UNIVERSITY OF VIRGINIA CHARLOTTESVILLE · PI THEODORESCU, DAN · 1997 to 2001
$217k
NCI NIH HHS CA075115
6 · The paper itself

Abstract

All organisms contain 1,000s of proteins and peptides in their body fluids, which undergo disease-specific changes. Advances in the understanding of the functional relevance of these polypeptides under different (patho)physiological conditions and the identification of indicative changes with disease would greatly enhance diagnosis and therapy. The low-molecular-weight proteome, also termed peptidome, provides a rich source of information. Due to its lower molecular weight, the peptidome can be assessed without the need for sample manipulation like tryptic digests. This advantage facilitates comparative analysis but it also raises technical challenges differing from those in proteomics. The first part of this manuscript, is focused on the low-molecular-weight urinary proteome and reviews methodological aspects of sample collection, preparation, analysis, and data evaluation. The second part summarizes the recent progress in the definition and identification of clinically relevant polypeptide markers.

Indexed as

BiomarkersHumansMass SpectrometryProteomeProteomicsUrineBiomarkersProteome

Identifiers

PMID17703310

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.